Compare · ESAB vs TMO
ESAB vs TMO
Side-by-side comparison of ESAB Corporation (ESAB) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ESAB and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $179.14B, about 35.5x ESAB ($5.05B).
- Over the past year, ESAB is down 34.3% and TMO is up 16.1% - TMO leads by 50.5 points.
- TMO has been more active in the news (17 items in the past 4 weeks vs 8 for ESAB).
- TMO has more recent analyst coverage (25 ratings vs 20 for ESAB).
- Company
- ESAB Corporation
- Thermo Fisher Scientific Inc
- Price
- $82.92-6.25%
- $482.27-2.41%
- Market cap
- $5.05B
- $179.14B
- 1M return
- -14.05%
- +6.57%
- 1Y return
- -34.32%
- +16.13%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- 2022
- News (4w)
- 8
- 17
- Recent ratings
- 20
- 25
ESAB Corporation
ESAB Corporation formulates, develops, manufactures, and supplies consumable products and equipment for use in cutting, joining, and automated welding, as well as gas control equipment. Its comprehensive range of welding consumables includes electrodes, cored and solid wires, and fluxes using a range of specialty and other materials; and cutting consumables, including electrodes, nozzles, shields, and tips. The company's fabrication technology equipment ranges from portable welding machines to large customized automated cutting and welding systems. It also offers a range of digital software and solutions to help its customers increase their productivity, remotely monitor their welding operations, and digitize their documentation. The company sells its products under the ESAB brand to various end markets, including general industry, construction, infrastructure, transportation, energy, renewable energy, and medical and life sciences. It offers its products through independent distributors and direct salespeople. ESAB Corporation was incorporated in 2021 and is based in Wilmington, Delaware.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest ESAB
- Director Rales Mitchell P acquired 3,426,451 shares and received a gift of 111,346 shares (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by ESAB Corporation
- Director Cummings Melissa converted options into 637 shares (SEC Form 4)
- Director Vinnakota Rajiv converted options into 637 shares, increasing direct ownership by 7% to 9,379 units (SEC Form 4)
- ESAB Corporation filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- ESAB Corporation Completes Acquisition of Eddyfi Technologies
- SEC Form SD filed by ESAB Corporation
- South Carolina Supreme Court Decision Raises Historic Asbestos Liability Questions for ESAB
- President, Fab Tech Biebuyck Olivier converted options into 2,362 shares and covered exercise/tax liability with 1,184 shares, increasing direct ownership by 6% to 20,556 units (SEC Form 4)
- SVP, General Counsel Jewell Curtis E converted options into 1,822 shares and covered exercise/tax liability with 894 shares, increasing direct ownership by 5% to 19,639 units (SEC Form 4)
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)